{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:22:02Z","timestamp":1791501722745,"version":"4.3.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T00:00:00Z","timestamp":1524441600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12032-018-1139-y","type":"journal-article","created":{"date-parts":[[2018,4,23]],"date-time":"2018-04-23T03:53:37Z","timestamp":1524455617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on\/1-week-off regimen for metastatic renal cell carcinoma"],"prefix":"10.1007","volume":"35","author":[{"given":"Kana","family":"Iwamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,23]]},"reference":[{"issue":"5","key":"1139_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4161\/cbt.2.5.446","volume":"2","author":"TJ Abrams","year":"2003","unstructured":"Abrams TJ, Lee LB, Murray LJ, et al. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471\u20138.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1139_CR2","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327\u201337.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"1139_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516\u201324. \n                    https:\/\/doi.org\/10.1001\/jama.295.21.2516\n                    \n                  .","journal-title":"JAMA"},{"key":"1139_CR4","doi-asserted-by":"publisher","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","volume":"27","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584\u201390. \n                    https:\/\/doi.org\/10.1200\/JCO.2008.20.1293\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"1","key":"1139_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol. 2006;24(1):25\u201335. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.02.2194\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"33","key":"1139_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/jjco\/hyt232","volume":"44","author":"T Kondo","year":"2014","unstructured":"Kondo T, Takagi T, Kobayashi H, et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma-comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. Jpn J Clin Oncol. 2014;44(33):270\u20137. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyt232\n                    \n                  .","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1139_CR7","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ejca.2014.01.025","volume":"50","author":"YG Najjar","year":"2014","unstructured":"Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. Eur J Cancer. 2014;50(6):1084\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2014.01.025\n                    \n                  .","journal-title":"Eur J Cancer"},{"issue":"3","key":"1139_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.juro.2013.08.090","volume":"191","author":"BJ Atkinson","year":"2014","unstructured":"Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611\u20138. \n                    https:\/\/doi.org\/10.1016\/j.juro.2013.08.090\n                    \n                  .","journal-title":"J Urol"},{"issue":"3","key":"1139_CR9","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s12032-015-0528-8","volume":"32","author":"H Miyake","year":"2015","unstructured":"Miyake H, Harada K, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. Med Oncol. 2015;32(3):78. \n                    https:\/\/doi.org\/10.1007\/s12032-015-0528-8\n                    \n                  .","journal-title":"Med Oncol"},{"issue":"10","key":"1139_CR10","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdv315","volume":"26","author":"S Bracarda","year":"2015","unstructured":"Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2\/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Ann Oncol. 2015;26(10):2107\u201313. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv315\n                    \n                  .","journal-title":"Ann Oncol"},{"issue":"268","key":"1139_CR11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/ajco.12686","volume":"12","author":"M Crumbaker","year":"2016","unstructured":"Crumbaker M, Guminski A, Gurney H, et al. Real-world experience of the feasibility and tolerability of the 2\/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. Asia Pac J Clin Oncol. 2016;12(268):47. \n                    https:\/\/doi.org\/10.1111\/ajco.12686\n                    \n                  .","journal-title":"Asia Pac J Clin Oncol"},{"issue":"5","key":"1139_CR12","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1007\/s12032-012-0236-6","volume":"29","author":"A Kawashima","year":"2012","unstructured":"Kawashima A, Tsujimura A, Takayama H, et al. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. Med Oncol. 2012;29(5):3298\u2013305. \n                    https:\/\/doi.org\/10.1007\/s12032-012-0236-6\n                    \n                  .","journal-title":"Med Oncol"},{"issue":"6","key":"1139_CR13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/cam4.302","volume":"3","author":"C Porta","year":"2014","unstructured":"Porta C, Levy A, Hawkins R, et al. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries. Cancer Med. 2014;3(6):1517\u201326. \n                    https:\/\/doi.org\/10.1002\/cam4.302\n                    \n                  .","journal-title":"Cancer Med"},{"issue":"11","key":"1139_CR14","first-page":"5043","volume":"33","author":"M Arakawa-Todo","year":"2013","unstructured":"Arakawa-Todo M, Yoshizawa T, Zennami K, et al. Management of adverse events in patients with metastatic renal cell carcinoma treated with sunitinib and clinical outcomes. Anticancer Res. 2013;33(11):5043\u201350.","journal-title":"Anticancer Res"},{"issue":"2","key":"1139_CR15","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115\u201324. \n                    https:\/\/doi.org\/10.1056\/NEJMoa065044\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"5","key":"1139_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","volume":"11","author":"H Ishihara","year":"2016","unstructured":"Ishihara H, Kondo T, Omae K, et al. Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment. Target Oncol. 2016;11(5):605\u201317. \n                    https:\/\/doi.org\/10.1007\/s11523-016-0430-0\n                    \n                  .","journal-title":"Target Oncol"},{"issue":"9","key":"1139_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.urolonc.2017.05.014","volume":"35","author":"H Ishihara","year":"2017","unstructured":"Ishihara H, Kondo T, Yoshida K, et al. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy. Urol Oncol. 2017;35(9):542. \n                    https:\/\/doi.org\/10.1016\/j.urolonc.2017.05.014\n                    \n                  . e1-542.e9.","journal-title":"Urol Oncol"},{"key":"1139_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026","author":"A Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026\n                    \n                  .","journal-title":"Eur J Cancer"},{"key":"1139_CR19","unstructured":"Cancer Institute N. Common terminology criteria for adverse events (CTCAE) common terminology criteria for adverse events v4.0 (CTCAE). 2009."},{"issue":"6","key":"1139_CR20","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1093\/jjco\/hyv045","volume":"45","author":"H Akaza","year":"2015","unstructured":"Akaza H, Naito S, Ueno N, et al. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol. 2015;45(6):576\u201383. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyv045\n                    \n                  .","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"1139_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722\u201331. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1303989\n                    \n                  .","journal-title":"N Engl J Med"},{"issue":"14","key":"1139_CR22","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","volume":"32","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Bono P, et al. Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study. J Clin Oncol. 2014;32(14):1412\u20138. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.50.8267\n                    \n                  .","journal-title":"J Clin Oncol"},{"issue":"3","key":"1139_CR23","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/jjco\/hyp146","volume":"40","author":"H Uemura","year":"2010","unstructured":"Uemura H, Shinohara N, Yuasa T, et al. A Phase II Study of sunitinib in japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety. Jpn J Clin Oncol. 2010;40(3):194\u2013202. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyp146\n                    \n                  .","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"1139_CR24","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ajco.12163","volume":"10","author":"S-H Lee","year":"2014","unstructured":"Lee S-H, Bang Y-J, Mainwaring P, et al. Sunitinib in metastatic renal cell carcinoma: an ethnic Asian subpopulation analysis for safety and efficacy. Asia Pac J Clin Oncol. 2014;10(3):237\u201345. \n                    https:\/\/doi.org\/10.1111\/ajco.12163\n                    \n                  .","journal-title":"Asia Pac J Clin Oncol"},{"issue":"12","key":"1139_CR25","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1093\/jjco\/hyq146","volume":"40","author":"Y Tomita","year":"2010","unstructured":"Tomita Y, Shinohara N, Yuasa T, et al. Overall survival and updated results from a phase II Study of sunitinib in Japanese patients with metastatic renal cell carcinoma. Jpn J Clin Oncol. 2010;40(12):1166\u201372. \n                    https:\/\/doi.org\/10.1093\/jjco\/hyq146\n                    \n                  .","journal-title":"Jpn J Clin Oncol"},{"issue":"5\u20136","key":"1139_CR26","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000330361","volume":"80","author":"HS Kim","year":"2011","unstructured":"Kim HS, Hong MH, Kim K, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. Oncology. 2011;80(5\u20136):395\u2013405. \n                    https:\/\/doi.org\/10.1159\/000330361\n                    \n                  .","journal-title":"Oncology"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-018-1139-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1139-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-018-1139-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T19:15:32Z","timestamp":1555960532000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-018-1139-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,23]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1139"],"URL":"https:\/\/doi.org\/10.1007\/s12032-018-1139-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,23]]},"assertion":[{"value":"4 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Tsunenori Kondo received honoraria from Pfizer, Bayer, and Novartis. All other authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this is a retrospective study, no formal consent is required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"78"}}